The Impact of Routine Protamine Administration in Transcatheter Aortic Valve Implantation (TAVI): Insights from the ACE-PROTAVI Trial As advancements in heart valve interventions continue, minimizing post-procedural complications remains a top priority for healthcare professionals. One area of growing interest is … Read More
Clinical Trials at your Fingertips!
Revolutionizing Medical Reference with Quick, Accessible Summaries of Landmark Clinical Trials - Right at Your Fingertips.
Latest Clinical Trials
TRAIN Trial: Transfusion Strategy in Acute Brain Injury
Understanding the TRAIN Trial: Transfusion Strategies in Patients with Acute Brain Injury In 2024, a groundbreaking study called the TRAIN Trial explored the impact of different transfusion strategies in patients suffering from acute brain injuries. This large, pragmatic, phase 3 … Read More
REDOX Trial: O2 for 24 Hours in Hypoxemia
REDOX Trial: Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia The REDOX trial is a phase IV, registry-based, randomized controlled study that examines whether long-term oxygen therapy (LTOT) for 24 hours per day provides better … Read More
BARACK-D Trial: Spironolactone in CKD
BARACK-D Trial: Low-Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease The BARACK-D trial is a prospective, randomized, open, blinded endpoint study that investigates the effects of low-dose spironolactone in patients with stage 3b chronic kidney disease (CKD) … Read More
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
AMBASSADOR Trial: Adjuvant Pembrolizumab in Urothelial Carcinoma
The AMBASSADOR trial is a phase 3 randomized clinical trial aimed at evaluating whether pembrolizumab as adjuvant therapy is more effective than observation in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. Study Details: Inclusion Criteria: Primary Outcome: Secondary … Read More
2R2 Trial: High-Dose, Short-Duration Rifampicin for TB Prevention
Published in: The LancetAuthors: Ruslami R et al.Publication Year: 2024Source: The Lancet, DOI: 10.1016/S2213-2600(24)00076-6 Objective of the Study:The 2R2 Trial was conducted to compare the safety and treatment completion rates of different doses and durations of rifampicin in patients who … Read More
LMS04 Trial: Doxorubicin-Trabectedin in Leiomyosarcoma
LMS04: Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Published in: New England Journal of MedicineAuthors: Pautier P et al.Publication Year: 2024Source: N Engl J Med 2024; 391:789-799 Objective of the Study:This trial, LMS04, aimed to refine the treatment strategy for patients … Read More
SWIFT Trials: Depemokimab in Severe Asthma
The SWIFT-1 and SWIFT-2 trials, published in The New England Journal of Medicine in 2024, investigated the efficacy of depemokimab in patients with severe uncontrolled asthma and an eosinophilic phenotype. Key Findings: Conclusion: Depemokimab significantly reduced the annualized rate of … Read More